[4] The most common side effects include injection site reactions, headache, and itching (pruritis).
[4] The US prescription label for marstacimab contains warnings and precautions about circulating blood clots (thromboembolic events), hypersensitivity, and embryofetal toxicity.
[4] The most common side effects include injection site reactions, headache, and itching (pruritis).
[4] In the participants receiving on-demand factor replacement during the first six months of the study, the estimated annualized bleeding rate was 38 compared to the estimated annualized bleeding rate during treatment with marstacimab of 3.2, showing that marstacimab was superior to on-demand factor replacement.
[4] The FDA granted the approval of Hympavzi to Pfizer Inc.[4] In September 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Hympavzi, intended for prophylaxis of bleeding episodes in people aged twelve years of age and older, weighing at least 35 kilograms (77 lb), who have severe hemophilia A or B.